Function lands $298m to expand into ‘medical intelligence’ by analyzing data from blood tests and body scans with AI.
Consumer health platform Function has reached a $2.5 billion valuation after securing a whopping $298 million Series B financing from a host of VCs, strategic backers, sports stars and celebrities. The company, which has grown rapidly since launching its biomarker testing membership in 2023, is expanding its model beyond diagnostics as it continues its mission to “empower everyone to live 100 healthy years.”
Function’s approach centers on harnessing comprehensive testing and advanced imaging. Members receive data on more than 160 biomarkers from two blood tests a year, spanning cardiovascular, endocrine and metabolic markers as well as nutrient levels, inflammation signals, toxin exposure and cancer-related indicators. According to the company, its members have completed more than 50 million lab tests to date.
The market for affordable preventive health programs is hotting up – in addition to Function, companies like Superpower and Hundred Health and others are also seeking to capitalize on the growing consumer appetite for data-driven health. Along with news of its funding round, Function announced it was reducing the cost of its annual membership from $499 to $365. The price change marks an attempt to “democratize” the practice of longitudinal testing and to establish ongoing physiological measurement as a foundational health behavior.
“Function is the most powerful approach I’ve seen in my career as a doctor,” said Dr Mark Hyman, Function’s Chief Medical Officer. “It delivers uncompromising depth with no shortcuts. This is the new standard for health.”
The company’s acquisition of Ezra earlier this year brought full-body MRI and CT imaging into its offering. Ezra’s FDA-cleared AI system shortens full-body MRI scan times to 22 minutes and is capable of identifying hundreds of potential conditions.
Integrating all these diagnostics is central to Function’s development of what it calls “medical intelligence,” a continuously updating system that uses AI to detect early biological changes that precede disease onset and convert those signals into guidance individuals can use in everyday decisions.
“This is the most important application of AI – helping people avoid suffering and preventable death,” said Function CEO Jonathan Swerdlin.
The company also announced a new Medical Intelligence Lab led by Daniel Sodickson, a radiologist known for inventing parallel MRI. The lab’s remit includes building predictive models that connect signals across bloodwork, imaging, wearable devices, IoT sensors and historical medical records.
“We’ve spent decades waiting until people are sick to act,” said Sodickson. “Medical Intelligence connects important signals – from blood to imaging to wearables – creating a continuously learning model of your health. It’s not AI replacing doctors; it’s clinical expertise amplified by intelligent systems that never stop learning.”
With the launch of the MI Lab, Function members can access a Private AI Chat feature that provides explanations and recommendations contextualized to a member’s health data, along with protocols that convert complex biomarker and imaging results into clear next steps. A record-uploading feature allows users to import external lab results and medical notes into a secure data vault that informs both the chat and personalized protocols.
The latest financing round, led by Redpoint Ventures, is intended to advance the Medical Intelligence platform and fuel Function’s continued expansion.
“Once I saw what Function can do, it felt irresponsible as a father and husband not to use it,” said Redpoint’s Elliot Geidt. “And I had to invest.”
“This is where technology, data, and medicine converge – turning years of fragmented health information into clarity and action,” said a16z’s Daisy Wolf. “Function isn’t just leading a new category in health; it’s setting the standard for how we understand, manage, and ultimately extend human health.”
